ERBB2 and breast carcinoma: However, recent studies have revealed that HER2-low breast cancer defined as tumors with immunohistochemistry (IHC) scores of 1+ or 2+ without gene amplification accounts for a substantial proportion (approximately 60%) of all breast cancer cases.